Interactive Investor

Physiomics Q&A: cancer expert explains progress

1st October 2021 11:39

Investor Meet Company from ii contributor

The management team at Physiomics share their view of annual results and answer your questions.  

Physiomics' (LSE:PYC) chief executive Jim Millen presents the company's annual results and answers a range of investor questions. The event, held on the 30 September 2021, is brought to you by our friends at Investor Meet Company.


Q&A   19:36 

About Company    

Physiomics PLC a United Kingdom-based firm providing services to pharmaceutical companies through outsourced systems and computational biology. The company is mainly engaged in the development of models to streamline the drug discovery and development process. It focuses on the development of Virtual Tumour Clinical used to predict optimal treatment for human clinical trials; Cardiac tox prediction service used to predict unwanted toxic side effects of drug candidates, and drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical treatments and their effects.

These articles are provided for information purposes only.  Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties.  The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.

Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.